Browse Studies — Arctuva

Phase 2

A Phase 2 Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Treatment-Experienced Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSC…

Non Small Cell Lung CancerAdvanced Non Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer+1 more

Estimated

~$10 – $8,750

Regeneron PharmaceuticalsNCT07154290

Phase 1

A Feasibility Phase I Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

Background: A type of drug called monoclonal antibody immune checkpoint inhibitors are often used in cancer treatment. These drugs help the body s immune syst…

Locally Advanced Alveolar Soft Part SarcomaMetastatic Alveolar Soft Part SarcomaLocally Advanced Non Small Cell Lung Cancer+7 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06066138

Phase 1

Phase I Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-Small Cell Lung Cancer

Background: Non-small cell lung cancer (NSCLC) can be hard to treat and is often fatal. People with NSCLC commonly have changes in the bacteria that populate …

Advanced Non Small Cell Lung Cancer

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05777603

Phase 2

Imaging of T-cell Activation With [18F]F-araG in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Undergoing PD-1/PD-L1 Directed Therapy

This pilot study uses \[18F\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC t…

Advanced Non Small Cell Lung Cancer

Estimated

~$10 – $8,750

CellSight Technologies, Inc.NCT06107374